Abstract
Objective
18F-fluorodeoxyglucose positron emission tomography (FDG-PET) [or PET/computed tomography (CT)] is more likely to show false-negative results when it is performed shortly after chemotherapy and/or radiotherapy because of “metabolic stunning”. The present study aimed to evaluate the influence of I-131 therapy on FDG uptake and the detection of recurrence or metastasis of differentiated thyroid cancer (DTC).
Methods
We retrospectively enrolled 16 consecutive FDG-PET/CT studies which had been performed in patients with DTC with elevated thyroglobulin (TG) but negative I-131 whole-body scan. All studies were performed under l-thyroxine suppression. The patients were divided into groups A and B for PET/CT performed within 4 months of I-131 therapy or no such therapy, respectively. Each lesion identified on PET/CT was characterized using a 5-point scale by visual analysis: 0 = definitely benign, 1 = probably benign, 2 = equivocal, 3 = probably malignant, and 4 = definitely malignant. The maximum standardized uptake value (SUVmax) in each lesion was also measured for semiquantitative analysis. We compared the visual grading and SUVmax of the lesion of highest FDG uptake between groups A and B.
Results
For visual analysis, group B had significantly more patients with an uptake score of 3 or 4 than group A (80% vs. 17%, P = 0.01). In addition, there were significantly more equivocal results from group A than from group B (67% vs. 10%, P = 0.02). If the patients with the highest uptake scores of 2, 3, and 4 were considered to be positive for local recurrence or metastasis, there would be no significant difference between the positive rates of groups A and B (83% vs. 90%, P = 0.7). However, the mean SUVmax of positive results was significantly lower for group A than for group B (3.1 ± 0.9 and 6.6 ± 3.5, respectively, P = 0.02).
Conclusions
The preliminary results suggested that FDG uptake in DTC may be negatively influenced by I-131 therapy within 4 months, resulting in lower FDG uptake and more equivocal results. Further studies are necessary to determine whether it is secondary to “metabolic stunning” caused by I-131 therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004;34:122–133.
Wood KA, Hoskin PJ, Saunders MI. Positron emission tomography in oncology: a review. Clin Oncol (R Coll Radiol) 2007;19:237–255.
Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004;34:180–197.
Lind P, Kohlfürst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 2006;36:194–205.
Ma C, Xie J, Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I wholebody scanning results? J Nucl Med 2005;46:1164–1170.
Spies WG, Wojtowicz CH, Spies SM, Shah AY, Zimmer AM. Value of post-therapy whole-body 131-I imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose 131-I therapy. Clin Nucl Med 1989;14:793–800.
Joensuu H, Ahonen A, Klemi PJ. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med 1988;13:502–506.
Feine U, Lizenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18 FDG and iodine-131 uptake in thyroid cancer. J Nucl Med 1996;37:1468–1472.
Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, et al. Resistance of [18f]-fluorodeoxyglucoseavid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001;11:1169–1175.
Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616–624.
Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET/CT in the Management of Thyroid Cancer. Clin Nucl Med 2007;32:690–695.
Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107–1113.
Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498–505.
Greven KM, Williams DW III, McGuirt WF, Keyes JW Jr, Williams DW III, Watson NE, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001;23:942–946.
Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998;39:815–822.
Beggs AD, Hain SF, Curran KM, O’Doherty MJ. FDG-PET as a “metabolic biopsy” tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging 2002;29:542–546.
Hain SF, Curran KM, Beggs AD, Fogelman I, O’Doherty MJ, Maisey MN. FDG-PET as a “metabolic biopsy” tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med 2001;28:1336–1340.
Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989–1995.
Petrich T, Börner AR, Weckesser E. Follow up of thyroid cancer patients using rhTSH-preliminary results. Nucl Med 2001;40:7–14.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hung, GU., Lee, KW., Liao, PY. et al. The influence of I-131 therapy on FDG uptake in differentiated thyroid cancer. Ann Nucl Med 22, 481–485 (2008). https://doi.org/10.1007/s12149-008-0149-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-008-0149-9